1. Biochemistry and Chemical Biology
Download icon

Thermodynamic evidence for a dual transport mechanism in a POT peptide transporter

  1. Joanne L Parker
  2. Joseph A Mindell
  3. Simon Newstead  Is a corresponding author
  1. University of Oxford, United Kingdom
  2. National Institutes of Health, United States
Research Article
  • Cited 31
  • Views 2,689
  • Annotations
Cite this article as: eLife 2014;3:e04273 doi: 10.7554/eLife.04273


Peptide transport plays an important role in cellular homeostasis as a key route for nitrogen acquisition in mammalian cells. PepT1 and PepT2, the mammalian proton coupled peptide transporters (POTs), function to assimilate and retain diet-derived peptides and play important roles in drug pharmacokinetics. A key characteristic of the POT family is the mechanism of peptide selectivity, with members able to recognise and transport >8000 different peptides. In this study, we present thermodynamic evidence that in the bacterial POT family transporter PepTSt, from Streptococcus thermophilus, at least two alternative transport mechanisms operate to move peptides into the cell. Whilst tri-peptides are transported with a proton:peptide stoichiometry of 3:1, di-peptides are co-transported with either 4 or 5 protons. This is the first thermodynamic study of proton:peptide stoichiometry in the POT family and reveals that secondary active transporters can evolve different coupling mechanisms to accommodate and transport chemically and physically diverse ligands across the membrane.


eLife digest

The cell membrane encases cells and functions as a protective barrier. Although this has the benefit of preventing harmful substances from entering a cell, it also keeps beneficial molecules out. The cell membrane therefore contains a system of different ‘gates’, called transporters, through which selected supplies can pass.

One large family of transporters, found in bacteria, mammals, and plants, is the ‘proton coupled oligopeptide transporter’ family, called POTs for short. These transport over 8000 types of small peptide molecule, each of which is made up of two or three smaller molecules called amino acids. The energy for this transport process is gained by simultaneously transporting charged ions called protons with the peptides. Because these transporters also recognize and transport various drugs, they are currently being investigated to discover whether they could be manipulated to increase how much of a drug is taken up into cells.

It remains unknown how the POT family of transporters imports so many different small peptides across the cell membrane, or how many protons are needed to transport a peptide. A study published earlier in 2014 has nevertheless provided some hints: it appears that small peptides adopt different shapes when bound to a bacterial POT transporter depending on whether they consist of two or three amino acids. This suggests that two different transport mechanisms operate from the same binding site, which may account for the wide variety of molecules that can be transported.

In a follow up to this work, Parker et al., including some of the researchers involved in the earlier 2014 work, now look in detail at how many protons this bacterial transporter uses to import these small peptides. This reveals that while the transport of peptides made of three amino acids requires three protons to also be moved through the transporter, the transport of peptides containing two amino acids requires four, or possibly five, protons. This challenges previous findings that these transporters transport one peptide for every proton, and further supports the idea that a single transporter can use more than one method to bind to and transport molecules. Whether other membrane transporters, particularly the human versions of the POT family, share this ability remains an open question.



Secondary active transporters are integral membrane proteins that couple the energy stored in an ion gradient to drive the uptake of a solute against its concentration gradient (Nicholls and Ferguson, 2013). This can be accomplished through either a symport mechanism, with the solute being moved in the direction of the driving ion, or antiport, where the solute movement is counter to that of the driving ion (Shi, 2013). The ion gradients utilised by secondary active transporters include proton (ΔμH+), sodium (ΔμNa+), or chloride (ΔμCl) gradients, which are in turn established through the action of the primary ATP driven P-, F-, V-, and A-type ion pumps (Voet and Voet, 2011). A fundamental characteristic of these systems is that, in general, transport is strictly coupled; the movement of solutes and ions is obligatory and one cannot be transported without the other. If these systems were to operate in a decoupled manner, they would act as leaks and dissipate the ion gradients across the membrane, quickly leading to cell death. Given the strict requirement for coupling solute binding and transport to ion movement, the stoichiometry of these mechanisms is normally a fixed ratio. Examples include the Escherichia coli lactose transporter, LacY, which transports lactose in a symport mechanism with one proton (Kaback et al., 2011) and EmrE, the small multidrug extrusion transporter, which moves both monovalent and divalent substrates in a 1:2 drug:proton stoichiometry (Rotem and Schuldiner, 2004).

A number of membrane proteins have been identified that recognise multiple structurally and chemically diverse solutes (Koepsell, 2013; Pelis and Wright, 2014). Prominent among these are the proton coupled oligopeptide transporters or POTs (Hillgren et al., 2013; Smith et al., 2013). POT family transporters are widely distributed within bacterial, fungal, and plant genomes where they are responsible for the uptake of di- and tri-peptides from the external environment (Daniel et al., 2006). Mammals contain four POT family transporters, PepT1 (SLC15A1), PepT2 (SLC15A2), PHT1 (SLC15A4), and PHT2 (SLC15A3). PepT1 and PepT2 are expressed at the plasma membrane, whereas PHT1 and PHT2 are found in lysosomal membranes (Daniel and Kottra, 2004). Throughout the POT family the transport mechanism and peptide binding site are highly conserved, with bacterial counterparts sharing ∼80% identity to human PepT1 and PepT2 within their peptide binding sites (Terada and Inui, 2012; Newstead, 2014). All POT family members studied to date transport their substrates into the cell in a coupled symport mechanism, driven by the proton electrochemical gradient. While a number of mutational studies on the mammalian PepT1 and PepT2 transporters address peptide recognition (Terada et al., 1996; Fei et al., 1997, 1998; Yeung et al., 1998; Uchiyama et al., 2003; Luckner and Brandsch, 2005; Kulkarni et al., 2007; Pieri et al., 2009), the question of how many protons are coupled to peptide transport remains unresolved; early studies using Caco-2 cell lines derives a ratio of greater than two protons per peptide (Thwaites et al., 1993). However due to experimental design, narrowing this figure to a more precise stoichiometry was not possible (Kottra et al., 2002). Electrophysiological studies using two electrode voltage clamping (TEVC) in Xenopus oocytes in tandem with radio ligand transport assays on non hydrolysable peptide (D-Phe-L-Gln/Glu/Lys or Gly-Sar) have reported stoichiometry ratios of 1:1 and 2:1 proton:peptide for neutral/basic and acidic di-peptides respectively for PepT1 (Fei et al., 1994; Steel et al., 1997; Chen et al., 1999). Similar experiments on PepT2 have given different ratios either D-Phe-L-ala of 2:1 and for D-Phe-L-Glu 3:1 (Chen JBC 1999) or 1:1 for D-Phe-L-Gln/Glu or Lys (Fei et al., 1999).

Recently, we reported two crystal structures of a bacterial POT family transporter, PepTSt, from Streptoccocus thermophilus, which revealed di- and tri-peptides interacting differently within the binding site (Lyons et al., 2014). Whereas the di-peptide L-Ala-L-Phe binds in a horizontal position with respect to the plane of the membrane, whilst the tri-peptide L-Ala-L-Ala-L-Ala resides in a vertical orientation and makes subtly different interactions within the binding site. This raised the interesting and to our knowledge unique proposition, that two different transport mechanisms may have evolved within the same binding site as a way to accommodate a diverse library of peptide ligands, >8000 (Ito et al., 2013). To address whether PepTSt could indeed operate using distinct mechanisms to drive di- and tri-peptides, we explored the coupling mechanism between protons and peptide in a reconstituted system, determining the coupling stoichiometries of protons and peptides. We show that whilst tri-peptide import is coupled to three protons, the mechanism for di-peptide import requires at least four and possibly five protons. These results provide further biochemical evidence that POT family transporters do operate via multiple mechanisms for coupling peptide transport to the proton gradient. The ability to couple different numbers of protons to structurally and chemically diverse ligands may explain how the POT family is able to accommodate and transport such a large library of di- and tri-peptides.


To address the question of stoichiometry, we developed a sensitive and robust assay to follow the proton movement during the transport cycle. Previously published peptide transport assays tend to follow peptide uptake using a radiolabeled peptide substrate. To instead follow proton movement, we monitored the internal pH with the ratiometric pH sensitive fluorophore, pyranine (Figure 1A and Figure 1—figure supplement 1). We first performed a number of control experiments to see whether our system could indeed follow proton coupled peptide transport into a liposome. Acidification of the lumen was only observed in the presence of peptide and a large hyperpolarized (negative inside) membrane potential imposed by adding the potassium ionophore valinomycin in the presence of a K+ gradient (Figure 1B,C and Figure 1—figure supplement 2). We did not see such acidification either in the absence of valinomycin or in the presence of amino acid (alanine) or tetra peptide (Ala-Ala-Ala-Ala), confirming that this transporter is indeed specific for di- and tri-peptide substrates (Figure 1C). PepTSt has been shown previously to transport Ala–Ala with a 10-fold higher activity than Ala-Ala-Ala as judged by IC50 values using tritiated Ala–Ala as a reporter (Solcan et al., 2012). We confirmed this 10-fold difference in uptake by using our proton-based assay, which can now report the direct uptake of any transported substrate rather than inferring substrate specificity through inhibition of Ala–Ala (Figure 1—figure supplement 3). This assay is also useful to study poor competitors of di-alanine for example, di-lysine where no competition could be observed previously (Solcan et al., 2012). Using this assay, we can now observe uptake of this substrate indirectly by monitoring the coupled proton movement (Figure 1C).

Figure 1 with 3 supplements see all
Monitoring peptide-coupled proton transport using the pH sensitive dye, pyranine.

(A) Experimental setup to monitor proton flux. PepTSt is reconstituted into liposomes loaded with pyranine and a high concentration of potassium ions (120 mM), the external solution contains peptide and a low potassium concentration (1.2 mM). On addition of valinomycin, the membrane becomes highly potassium permeable, generating a hyperpolarised membrane potential (negative inside) this drives the uptake of peptide with protons, protonating the pyranine dye and altering its fluorescent properties. (B) Representative pyranine fluorescence traces produced from the set up described in (A) indicating that acidification of the liposomal lumen only occurs in the presence of a valinomycin (black arrow)-induced membrane potential with peptide. The Y axis indicates the fluorescence ratio as stated in the methods. (C) PepTSt can only transport di- and tri-peptides. To initiate transport, valinomycin was added to all experiments at the time indicated by the black arrow and the external substrate concentration was 0.2 mM. Data were normalised to the first time point for ease of comparison.


Since PepTSt is an electrogenic transporter, we predict that imposition of a membrane potential in the presence of a pH gradient should drive uphill substrate transport. By loading the liposomes with high concentration of peptide and imposing a large hyperpolarising membrane potential (negative inside), we observe acidification of the lumen, indicating that the voltage can drive PepTSt-mediated transport against a 100-fold peptide gradient (Figure 2A). Importantly, we can also manipulate this system to see protons leaving the liposomal lumen as would be expected under an oppositely orientated membrane potential (positive inside). With an assay system set up where we could drive transport in predicted directions, we were now in a position to assess proton:peptide stoichiometry by measuring the equilibrium potential for proton flux using pyranine at a series of membrane voltages, set at the start of the assay with the appropriate potassium ion concentration gradient and the addition of valinomycin. This type of assay was used previously to address the stoichiometry of a lysosomal Cl−/H+ antiporter, CLC-7 (Graves et al., 2008).

Figure 2 with 1 supplement see all
Peptide transport depends on the imposed voltage.

Proteoliposomes in the presence of a 100-fold peptide gradient (0.1 mM outside and 10 mM inside) and no pH gradient (pH 6.8 both inside and outside). No proton flux occurs until the transmembrane potential is shunted by addition of valinomycin (green trace, val added at black arrow). PepTSt can drive transport of peptides (and protons) against this gradient into the interior of the liposome using the proton electrochemical gradient when a negative voltage is imposed by valinomycin addition. (negative inside—yellow line). Further addition of peptide (0.5 mM) results in additional uptake (grey arrow). When a large (inside) positive voltage is applied (same peptide and pH gradients), peptides (and protons) exit the liposome (pink line).


We assume that PepTSt operates via the coupled mechanism, nHout + mPepout ⇔nHin + mPepin, where the relative stoichiometry of protons:peptide is n/m. For this coupled system, the equilibrium potential is defined as the voltage at which there is no net substrate flux. This voltage, also known as the reversal potential (ΔΨ), is independent of the reaction mechanism. Rather, it depends only on the concentrations of protons and substrate and on the coupling stoichiometry with the form: ΔΨ = 60{[pHin − pHout] − m/n log ([Pep]in/[Pep]out)}, where m and n are the stoichiometric coefficients in the chemical reaction above and ΔΨ is in mV (see derivation in Figure 2—figure supplement 1). For a given combination of pH and peptide gradients this equation predicts a voltage at which no net pH change will occur; voltages above and below that value should produce inward or outward proton flux, depending on the voltage. Conversely, if at a series of voltages (set using K+/valinomycin), we observe acidification/no flux/alkalinzation, we can derive the relative stoichiometry of PepTSt for protons and peptide. We performed such experiments for the neutral peptide, Ala-Ala-Ala with no net pH difference between the inside and outside of the liposome and a 100-fold peptide gradient (higher concentration inside) and observed an absence of proton flux at a membrane potential of−40 mV (inside negative) which corresponds to a 3:1 proton:peptide stoichiometry (Figure 3A and Figure 3—source data 1). In contrast, voltages corresponding to reversal potentials for stoichiometries of 2:1 and 4:1 produced clearly distinguishable inward and outward fluxes respectively, strongly pointing to a 3:1 stoichiometry for the transporter. A very different combination of proton and peptide gradients, where we now included a proton gradient, also (pH more acidic outside) gave the same stoichiometry of 3:1 for the same tri-alanine peptide (Figure 3B). We also obtained this three proton:peptide stoichiometry for a different tri-peptide substrate, Ala-Leu-Ala (Figure 3C).

Tri-peptides are co-transported with three protons.

The potassium gradient across the liposomes was varied in order to set the desired voltages (on valinomycin addition, black arrow) to achieve no net proton movement (indicated by the black line at FR of 1.0). The number next to the voltages are the proton:peptide stoichiometry that would reverse at that voltage. The internal peptide concentration (10 mM) (Tri-ala for A and B, and Ala-Leu-Ala for C) was 100-fold above that of the external concentration and the pH was inside 6.8, outside 6.8 (for A and C) and 6.0 (for B). Representative traces are shown for each experiment, which were repeated at least three independent times. The line graph for each experiment represents the mean change in fluorescence at time point 60 s and S.E.M. is indicated. Grey arrows indicate the addition of more peptide, to show that the system can be further manipulated.


We went on to determine the proton:peptide stoichiometry of PepTSt when transporting di-peptide substrates. However, when we performed experiments with the same gradients as our initial tri-peptide measurements only now with the neutral peptide Ala–Ala, we still observed transport at a voltage of −40 mV, where before we saw no net proton flux for tri-alanine. Transport is still also occurring at −30 mV which under these conditions would correspond to a proton:peptide stoichiometry of 4:1 and where we saw proton influx for tri-alanine (Figure 4A). Therefore, surprisingly, the stoichiometry of protons to peptides in PepTSt appears to be different for tri-Ala as compared with di-Ala. Further experiments to try to pin down the number of protons being co-transported with di-alanine lead to slightly ambiguous results, as increasing proton:peptide stoichiometries predict decreasing increments in reversal potential. These are, in turn, harder to generate reproducibly with our valinomycin/K+ system. We performed experiments with voltages set at reversal potentials predicted for symport ratios of 5 and 6 protons:peptide and proton flux was minimal at −20 mV (6 protons) but it is hard to be able to fully distinguish. Importantly, the system can still be driven in the opposite direction with higher voltages (0 mV, Figure 4B). Regardless of whether the actual stoichiometry is 5 or 6 protons:peptide, these experiments strongly suggest that the stoichiometry is higher for di-peptides than for tri-peptides. We confirmed this higher ratio for di-peptide transport using the substrate Ala–Phe (Figure 4C). Again transport is clearly observed at a membrane potential at −30 mV, so the stoichiometry for di-peptide transport by PepTSt is greater than four protons, clearly different from that of tri-peptides.

Di-peptide transport requires more protons than tri-peptide.

The potassium gradient across the liposomes was varied in order to set the desired voltages (on addition of valinomycin, black arrow) to achieve no net proton movement (indicated by the black line at FR of 1.0). Only voltages that indicate a stoichiometry of proton:peptide of greater than 5:1 showed either no net movement of protons or reversal for both Ala–Ala (A, B) and Ala–Phe (C) di-peptides. Representative traces are shown for each experiment, which was repeated at least three independent times. The line graph for each experiment represents the mean change in fluorescence at time point 60 s and S.E.M. is indicated. Grey arrows indicate the addition of more peptide, to show that the system can be further manipulated.


The reversal potential equation above predicts that if ΔΨ = 0, then [Pepin]/[Pepout] = ([H+out]/[H+in])n, where n is the number of protons transported per peptide. Therefore, if our results are truly indicative of higher coupling ratios for di-peptides than for tri-peptides, the same proton electrochemical gradient should accumulate di-peptides to a higher steady-state concentration than tri-peptides. We tested this prediction by measuring the uptake of radiolabeled di- and tri-peptides in the presence of a fixed, 1-unit pH gradient (acid outside). As shown in Figure 5, we find dramatically higher uptake of the di-peptide in this gradient, conclusively supporting the idea that different length peptides couple to the proton gradient with differing stoichiometries.

Steady-state accumulation of di- vs tri-alanine.

Peptide transport was driven by an inwardly directed proton gradient in saturating amounts of peptide. Uptake was measured via scintillation counting using radiolabeled peptides (3H for di-alanine and 14C for tri-alanine) and converted to pmols peptide transported per unit time.


A different coupling stoichiometry for di- vs tri-peptides raises an interesting question of whether different amino-acid side chains within the transporter are required for di-peptide vs tri-peptide transport. PepTSt contains six-protonatable side chains within its binding site (Glu 22, 25, 299, 300, 400, and K126, Figure 6A). All of these with the exception of Glu299 are conserved across the PTR family from bacteria through to mammalian PepT1 and PepT2. Previous biochemical studies have shown that in PepTSt this non-conserved residue is likely to be involved in structural and/or stability features specific to this protein as mutation of this residue results in no expression of the protein. Glu400 and Lys126 are likely to form a salt bridge that stabilises the outward open confirmation of the transporter, a feature that would be conserved regardless of the substrate. Glu300 has been shown to interact with both a di-peptide and a tri-peptide substrate and therefore likely to be involved in the transport mechanism for both di- and tri-peptides and has been shown to be important for di-alanine transport previously (Solcan et al., 2012; Doki et al., 2013). This leaves Glu22 and Glu25 as candidates for differential effects on di- and tri-peptide transport. Previously these residues have been shown to be important for proton coupling for di-alanine, however, here we also found that mutating either of these residues to alanine yielded proteins unable to catalyse proton coupled tri-alanine transport (Figure 6B). Therefore, despite different proton:peptide stoichiometries are apparently required for di- and tri-alanine transport, all five protonatable side chains within the binding site of PepTSt are likely to be important for the transport mechanism.

Figure 6 with 1 supplement see all
Model for proton:peptide symport.

(A) Crystal structure of PepTSt with bound Ala–Phe peptide (orange) (PBD 4D2C) showing the protonatable side chains within the binding site (green). Helices TM5 and TM8 have been removed for clarity. (B) E22A and E25A variants of PepTSt are unable to couple proton movement to the transport either di-alanine or tri-alanine. (C) Ala–Phe and Ala-Ala-Ala adopt different orientations within the binding site of PepTSt. Two views of PepTSt shown in the plane of the membrane and rotated 90°, with Ala-Ala-Ala (blue) and Ala–Phe (magenta) shown as sticks. Helices TM5 and TM8 have been removed for clarity. (D) Model for proton:peptide symport in PepTSt. Di-peptides transport requires at least four protons, whereas tri-peptides require only three, suggesting this is the lowest number of protons required to drive the conformational changes required for alternating access transport. Essential residues are indicated; residues involved in the potential stabilising salt bridges are labelled in blue and red, whereas protonatable side chains are labelled in purple.



A dual transport model for proton coupled peptide symport in the POT family

A fundamental aspect of any transport mechanism is its coupling stoichiometry, how many ions are moved for each molecule of solute, as this information is necessary to generate reasonable mechanistic models for the transporter under study. Previous electrophysiological recordings on PepT1 and PepT2 have focused their attention on di-peptide substrates and suggest a 1:1 proton:peptide stoichiometry in PepT1 for neutral peptides and either 1:1 or > in PepT2 (Smith et al., 2013). Recent crystal structures and functional data on a bacterial POT family transporter, PepTSt, a homologue of PepT1 and PepT2, revealed that peptides could adopt different orientations within the binding site (Figure 6C). Whereas tri-alanine was observed adopting a vertical position and coordinated by 4 hydrogen bonds, the di-peptide L-Ala-L-Phe was held in a more horizontal position and coordinated through a more extensive network of interactions involving electrostatic interactions with conserved side chains from the N- and C-terminal bundles (Lyons et al., 2014). This raised the possibility that PepTSt could transport peptides using two different mechanisms operating within the same binding site and has important implications for understanding proton coupled transport more generally within the POT family.

Here, we used a reconstituted proteoliposome system to accurately measure reversal potentials for peptide-coupled proton fluxes and found that di- and tri-peptides are transported using different proton stoichiometries. Assuming that our measurements on two sets of distinct di- and tri-peptides reflect the stoichiometries in general, our new data add to our previous multiple binding mode model by showing that tri-peptides are transported using three protons, whereas di-peptides are transported using four or possibly even five protons per cycle. It is important at this stage to highlight that our experiments cannot discriminate between protons that come through the transporter and those that may come through bound to the peptide. However, even if some protons are being moved on the peptide as opposed to being required to rearrange interaction networks during transport, our results still demonstrate that different numbers of protons are moved during the coupled transport of neutral di- vs tri-peptides, which we ascertain establishes a fundamental difference in the way this protein handles these two ligands.

Interestingly, all five of the protonatable residues within the binding site are required for transport as none could be mutated and still allow for the transport of either peptide. This could be due to movement of the three protons within the binding site to different side chains, perhaps to help re-orientate the tri-peptide as the transporter transitions through its conformational cycle. Indeed if you overlay the crystal structure of the tri-alanine structure with a model of the outward open structure (Figure 6—figure supplement 1), tri-alanine in this position would obstruct the closing of the intracellular gate through disruption of the intracellular stabilising salt bridge (formed between Lys126 (TM4) and Glu400 (TM10)). Therefore, we suggest that for tri-alanine to be transported across the membrane, it is likely to undergo a change in its vertical binding position, to allow for closure of the transporter.

The question then arises as to the functional role of the protons in the transporter. We have previously identified six-protonatable side chains present in the binding site of PepTSt (Figure 6A), with all but Glu299 being conserved across the POT family (Solcan et al., 2012). It would be tempting therefore, on the basis of simplicity, to predict that our data suggest only three side chains are protonated during tri-peptide transport, and four/five in di-peptide transport. However, we do not believe this to be the case. Our attempts to systematically remove the protonable side chains Glu22 and Glu25 on TM1, which form part of the conserved ExxERF motif but do not interact with either of the di-peptide or tri-peptide in the crystal structures (Lyons et al., 2014), resulted in inactive transporters (Figure 6B). Previous studies have shown that mutating any of the remaining side chains; Lys126, Glu300, and Glu400 also result in inactive proton coupled transport (Solcan et al., 2012). We conclude from these results that all of the protonatable side chains are required for transport regardless of substrate. However, the observation that tri-peptides can be moved using only three protons delineates the minimal number of de-protonation events that are required to drive the conformational changes that re-orientate the binding site. In this model, the remaining protonatable groups remain proton-bound throughout the transport cycle when tri-peptides are transported. On the basis of the new data presented here, we can add further mechanistic insight into our earlier model for peptide transport that we have summarised in Figure 6D. Alternating access within the POT family is physiologically driven by the proton electrochemical gradient, with defined conformational states stabilised through conserved pairs of salt bridges that act to coordinate the opening and closing of the intracellular and extracellular gates (Newstead, 2014). Starting from the outward open conformation the binding site is accessible to the extracellular side of the membrane, and the intracellular gate is closed and stabilised by a possible salt bridge between Lys126 (TM4) and Glu400 (TM10). Functional studies have revealed that in another bacterial POT family transporter, from Geobacillus kaustophilus, GkPOT, that the equivalent glutamate to Glu300 is protonated and may be required to allow the binding of peptide (Doki et al., 2013). Considering the minimal three-proton model for tri-peptide transport we propose, it seems reasonable to suggest that proton transfer from Glu300 to Glu400 during transport may occur to couple closing of the extracellular gate with opening of the intracellular one. This would account for one proton. The other two we suggest may come from Lys126 and either of Glu22 or Glu25. Our evidence is that in previous functional studies we showed that either of these side chains could be mutated to alanine with only a slight reduction in counterflow transport but complete loss of proton coupled peptide uptake (Solcan et al., 2012), behaviour classically used to identify side chains required for proton coupled uptake. In the case of di-peptides, additional deprotonation is clearly required. We conjecture that this is the result of the tighter coordination observed in the di-peptide complex structure compared to that for the tri-peptide (Figure 6C) and maybe one reason why this binding site is so sensitive to mutation in our assays.

An adaptable coupling mechanism, such as we propose, might have been an important component that enabled the POT family to adapt its binding site to accommodate structurally and chemically diverse molecules for nutritional assimilation. Whilst in bacterial, fungi, and mammals POT family homologues are responsible for peptide uptake, in plants this family has evolved to recognise widely diverse molecules, including nitrate, glucosinylates, hormones, and peptides (Léran et al., 2014; Sun et al., 2014; Parker and Newstead, 2014). This may explain why mammals use the POT family homologues PepT1 and PepT2, as coupling peptide transport to the proton gradient appears to facilitate a promiscuous binding site that can adapt to chemically diverse side chain groups more easily than sodium coupled transporters, which require well-defined binding sites for the cation.

Materials and methods

Reconstitution of PepTSt

Request a detailed protocol

For reconstitution, PepTSt purified in the detergent DM (Solcan et al., 2012) was mixed in a 60:1 ratio (lipid:protein) with lipid vesicles composed of a mixture of POPE and POPG (in a 3:1 ratio). These lipids were chosen as they had been previously reported to form proton tight liposomes (Tsai and Miller, 2013). We confirmed this in our liposomes (Figure 1—figure supplement 1). The protein:lipid mix was diluted into a large volume of reconstitution buffer (50 mM potassium phosphate 6.8), and proteoliposomes were harvested by ultracentrifugation (>200,000×g) for 3 hr. Pelleted liposomes were resuspended at 0.5 µg/µl (protein) and dialysed extensively against reconstitution buffer (24 hr with two changes of buffer). Proteoliposomes were recovered and subjected to three rounds of freeze thawing before storage at −80°C.

Transport assays

Request a detailed protocol

Proteoliposomes were harvested and resuspended in inside transport buffer (5 mM Hepes pH 6.8, 2 mM MgSO4, 1 mM Pyranine (trisodium 8-hydroxypyrene-1,3,6-trisulfonate) also containing the desired potassium concentration (KCl) and peptide concentration) and subjected to three rounds of freeze thaw in liquid nitrogen and then extruded through a 0.4-µm membrane. Pyranine is a fluorescent pH indicator dye which is water soluble and can be trapped within liposomes. Acidification of the lumen of the liposome is indicated by a decrease in the ratio of fluorescence measured at 510 when excited at either 460 or 415. After extrusion the liposomes were harvested and excess pyranine removed through gel filtration using a superdex-25 column pre-equilibrated in inside transport buffer without pyranine. For the assays the liposomes were diluted into external transport buffer in a 0.85-ml micro cuvette with a small magnetic flea (5 mM HEPES pH 6.8 or 5 mM MES pH 6.0, 2 mM MgSO4 and the desired amount of KCl to obtain the desired potassium gradient, ionic strength was kept equal across the liposome using NaCl). Transport was initiated using 1 µM valinomycin, and fluorescence was read at excitation 460 and 415 emission 510 in a Cary eclipse fluorimeter with continual stirring. To examine the data, the data were exported into Graphpad and the fluorescence was measured at 510 excitation 460 divided by that measured at 415 excitation, indicated at FR in the results. To compare multiple conditions, the data were normalised to 1 (from the first reading) for each experiment. Representative raw data are shown in Figure 1—figure supplement 2. For each individual experiment, the mean value was calculated from 55 to 65 s and this was repeated for each replicate (minimum of three) to generate an overall mean and S.E.M, which is plotted as a line graph on each figure.

Transport assays using radiolabelled peptide

Request a detailed protocol

Proteoliposomes were harvested and resuspended in inside buffer (5 mM HEPES pH 7.5, 2 mM MgSO4, 75 mM KCl) and subjected to three rounds of freeze thaw in liquid nitrogen and then extruded through a 0.4-µm membrane. For the assays, the liposomes were diluted into external transport buffer (5 mM MES pH 6.5, 2 mM MgSO4 75 mM KCl). Peptide, to a final concentration of 0.5 mM containing a tracer amount of either 3H-di-alanine (specific activity 30 Ci/mmol) or 14C-tri-alanine (specific activity 55 mCi/mmol), was added with 1 µM valinomycin and time points taken. The assays were performed at 22°C. Time points were taken and stopped by addition into 2 ml 0.1 M LiCl and filtering immediately through a 0.4-µm membrane in a vacuum manifold. The filters were washed twice with 2 ml of LiCl prior to scintillation counting in Ultima Gold (Perkin elmer). The amount of peptide transported into the liposomes was calculated based on specific activity for each peptide as detailed by the manufacturer and counting efficiency for the radioisotope in Ultima Gold counted in a Wallac scintillation counter (3H 45% counting efficiency, 14C 98%). Experiments were performed four times to generate an overall mean and S.E.M.


  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Molecular insights into proton coupled peptide transport in the PTR family of oligopeptide transporters
    1. S Newstead
    Biochimica Et Biophysica Acta, 10.1016/j.bbagen.2014.05.011.
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    Stoichiometry and pH dependence of the rabbit proton-dependent oligopeptide transporter PepT1
    1. A Steel
    2. S Nussberger
    3. MF Romero
    4. WF Boron
    5. CA Boyd
    6. MA Hediger
    The Journal of Physiology 498:563–569.
  29. 29
  30. 30
    Chapter Eight—Recent Advances in structural Biology of peptide transporters
    1. T Terada
    2. KI Inui
    Vol 70, Elsevier.
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    Biochemistry (4th edition)
    1. D Voet
    2. JG Voet
    Hoboken, NJ: John Wiley & Sons.
  36. 36

Decision letter

  1. John Kuriyan
    Reviewing Editor; Howard Hughes Medical Institute, University of California, Berkeley, United States

eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see review process). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled “One transporter, two mechanisms: Thermodynamic evidence for a dual transport mechanism in a POT peptide transporter” for consideration at eLife. Your article has been evaluated by John Kuriyan (Senior editor) and 2 reviewers. The editor and the reviewers find that the paper is of interest, and that it may be suitable for publication in eLife. They do, however, have some concerns about whether the principal conclusion, that the transport of dipeptides and tripeptides is coupled to different stoichiometries of protons, is based on a completely reliable interpretation of the data. Please consider the point referred to in the review below as major concern No. 1, and respond to us by email to the eLife editorial office telling us how you might deal with this particular issue. The editor and the reviewers will consider your response before reaching a decision on the paper.


The aim of the study presented by Newstead and colleagues is to determine the stoichiometry of a bacterial peptide/H+ symporter. The authors used a ratiometric fluorescence dye to record pH changes in liposomes. They demonstrated that the transporter transports protons when there is a voltage difference across the membrane, mediated by K+ and valinomycin. They also found that proton transport depends on the presence of peptides (Figure 1). The stoichiometry between peptides and protons was determined by finding the voltage at which H+ flux is zero (defined as the reversal potential) at known peptide and proton gradients. By relating the chemical potential difference of the peptide inside and out to the electrochemical driving force of the protons (which will depend on the number of protons per peptide), the stoichiometry (m/n) can be determined from the equation described.

This manuscript adds mechanistic novelty to Newstead's recent structures of proton-coupled peptide transporter family (POT) proteins by establishing an intriguing oddity concerning the transport mechanism of the two types of peptide substrates handled by PepT-type transporters. The previous crystal structures of the S. thermophilus PepT had shown that two classes of substrates, neutral di-peptides and tri-peptides, bind in different ways to the transport region. This raised questions about how the transporter, which handles a huge diversity of di- and tripeptides, manage this feat of nonspecificity within and specificity among substrate classes. Now, using an elegant assay in a reconstituted liposome-flux system, the authors show an important difference in H+-peptide stoichiometry between dipeptides (i.e., Ala-Ala) and tripeptides (Ala-Ala-Ala or Ala-Leu-Ala). This implies, under the assumption of strict H+ coupling for both substrate types that substantially separate transport mechanisms have evolved within the same protein. Given that assumption, that is a novel insight.

The authors also present experiments to identify specific residues that may be involved in handling the “extra” protons for the dipeptides. They mutate various protonatable residues that are seen to be close in the structures to the dipeptides, in hopes of finding mutants that abolish H+ coupling for the dipeptides, while preserving it for the tripeptides. Although no such specific residues emerged from these mutants, the effort and its “negative result” is nevertheless worthwhile to report.

Major concerns:

1) As written, there remains a major logical soft-spot in the central conclusion. The manuscript is properly explicit in stating the basic assumption underlying the stoichiometry measurement: that the transporter is fully, obligatorily coupled for both substrates. It is this assumption that leads to the equation on p 5 for the reversal potential, the zero-flux condition at thermodynamic equilibrium. If this assumption is valid, then all the conclusions offered here follow as the night the day. But what if it isn't? An alternative possibility is that the “less active” dipeptide substrate might show a higher H+/peptide stoichiometry because it is imperfectly coupled, and that 2 protons “slip through” on average for every transport cycle in which 3 protons are actually mechanistically coupled. This would create a nonequilibrium situation in which the coupled protons and the leak protons have different reversal potentials, and the observed zero-flux voltage lies between the two. In such a case of partial slippage; a situation known to exist, for example, in mutants of CLC transporters, the actual mechanism of transport would be identical for both di- and tripeptides, and so it would be invalid to tout this as an example of “one transporter, two mechanisms.”

A fairly simple and quick experiment could plug this logical hole (if the result comes out in the hoped-for way). If dipeptide transport is truly coupled to more protons than tripeptide transport (5 vs 3, say), then radiolabeled dipeptide should be accumulated to far higher steady levels than tripeptide for the same proton electrochemical gradient. If, on the other hand, leak protons are wasted while the mechanism's coupling is the same for both substrates, then di and tri-peptides should be similarly accumulated in a basic concentrative uptake assay. Even a qualitative result that could settle the issue.

2) This assay seems to work fine for two neutral tri-peptides, A-A-A and A-L-A. But the results are puzzlingly ambiguous for di-peptides that are known to be better substrates than tri-peptides. It seems that the di-peptides have a different stoichiometry than that of the tri-peptides; however, the authors could not determine the exact reversal potential for the di-peptides.


Author response

We performed the key experiment suggested by the reviewers to test our model of different stoichiometries for different substrates, namely a test of whether the peptide transporter, PepTSt, could accumulate di-peptides to a higher concentration than tri-peptides for the same proton electrochemical gradient. The result of this experiment indeed confirms that PepTSt does indeed operate via two thermodynamically distinct mechanisms of peptide transport, and strengthens our conclusions. We have detailed the results in a new Figure 5.

1) […] A fairly simple and quick experiment could plug this logical hole (if the result comes out in the hoped-for way). If dipeptide transport is truly coupled to more protons than tripeptide transport (5 vs 3, say), then radiolabeled dipeptide should be accumulated to far higher steady levels than tripeptide for the same proton electrochemical gradient. If, on the other hand, leak protons are wasted while the mechanism's coupling is the same for both substrates, then di and tri-peptides should be similarly accumulated in a basic concentrative uptake assay. Even a qualitative result that could settle the issue.

We agree with the reviewers that this is an important experiment and as detailed above we have included this data in a new figure, Figure 5. The results clearly show that di-alanine peptide is concentrated to a significantly higher level than tri-alanine for the same proton electrochemical gradient. We are confident that this new result substantially strengthens our original hypothesis and the conclusions in the paper.


Article and author information

Author details

  1. Joanne L Parker

    Department of Biochemistry, University of Oxford, Oxford, United Kingdom
    JLP, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.
  2. Joseph A Mindell

    Membrane Transport Biophysics Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, United States
    JAM, Conception and design, Analysis and interpretation of data, Drafting or revising the article
    Competing interests
    The authors declare that no competing interests exist.
  3. Simon Newstead

    Department of Biochemistry, University of Oxford, Oxford, United Kingdom
    SN, Conception and design, Analysis and interpretation of data, Drafting or revising the article
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.


Wellcome Trust (102890/Z/13/Z)

  • Simon Newstead

The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.


SN is a Wellcome Trust Investigator (102890/Z/13/Z). JAM is funded through the NINDS Intramural Program. We thank Chris Mulligan for helpful comments on the manuscript.

Reviewing Editor

  1. John Kuriyan, Howard Hughes Medical Institute, University of California, Berkeley, United States

Publication history

  1. Received: August 7, 2014
  2. Accepted: December 1, 2014
  3. Accepted Manuscript published: December 2, 2014 (version 1)
  4. Version of Record published: December 22, 2014 (version 2)


This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.


  • 2,689
    Page views
  • 504
  • 31

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Syafiq Abd Wahab, Dirk Remus
    Research Article Updated

    Eukaryotic replication origins are licensed by the loading of the replicative DNA helicase, Mcm2-7, in inactive double hexameric form around DNA. Subsequent origin activation is under control of multiple protein kinases that either promote or inhibit origin activation, which is important for genome maintenance. Using the reconstituted budding yeast DNA replication system, we find that the flexible N-terminal extension (NTE) of Mcm2 promotes the stable recruitment of Dbf4-dependent kinase (DDK) to Mcm2-7 double hexamers, which in turn promotes DDK phosphorylation of Mcm4 and −6 and subsequent origin activation. Conversely, we demonstrate that the checkpoint kinase, Rad53, inhibits DDK binding to Mcm2-7 double hexamers. Unexpectedly, this function is not dependent on Rad53 kinase activity, suggesting steric inhibition of DDK by activated Rad53. These findings identify critical determinants of the origin activation reaction and uncover a novel mechanism for checkpoint-dependent origin inhibition.

    1. Biochemistry and Chemical Biology
    Nam Chu et al.
    Research Article

    Akt is a critical protein kinase that governs cancer cell growth and metabolism. Akt appears to be autoinhibited by an intramolecular interaction between its N-terminal pleckstrin homology (PH) domain and kinase domain, which is relieved by C-tail phosphorylation, but the precise molecular mechanisms remain elusive. Here we use a combination of protein semisynthesis, NMR, and enzymological analysis to characterize structural features of the PH domain in its autoinhibited and activated states. We find that Akt autoinhibition depends on the length/flexibility of the PH-kinase linker. We identify a role for a dynamic short segment in the PH domain that appears to regulate autoinhibition and PDK1-catalyzed phosphorylation of Thr308 in the activation loop. We determine that Akt allosteric inhibitor MK2206 drives distinct PH domain structural changes compared to baseline autoinhibited Akt. These results highlight how the conformational plasticity of Akt governs the delicate control of its catalytic properties.